Cipher Pharmaceuticals Inc.
CPHRF
Rank in Stocks
#15715
Cipher Pharmaceuticals Inc., founded in 2000 and based in Oakville, Canada,... Cipher Pharmaceuticals Inc., founded in 2000 and based in Oakville, Canada, operates as a specialized pharmaceutical enterprise. The company markets a diverse portfolio of commercial therapeutic solutions. These include Epuris (CIP-ISOTRETINOIN), formulated for severe acne; Ozenoxacin, targeting impetigo in both adult and pediatric patients; Actikerall, prescribed for palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a topical cream designed to mitigate unwanted facial hair growth in women; BRINAVESS, utilized for restoring sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet medication. Beyond its directly marketed offerings, Cipher's portfolio encompasses various licensed products, such as CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), used in the management of hyperlipidemia, a lipid metabolism disorder; and Conzip/Durela (CIP-Tramadol), indicated for the relief of moderate to moderately severe pain. Looking to the future, Cipher maintains a robust developmental pipeline, which includes Trevyent, a vasodilatory prostacyclin analogue aimed at treating pulmonary arterial hypertension; CF-101, under investigation for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for onychomycosis; and DTR-001, a novel cream for tattoo removal.
Share Price
$9.76
Last synced: 2026-11-09
Market Cap
$247.47M
Change (1 day)
4.16%
Change (1 year)
1.14%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cipher Pharmaceuticals Inc. (CPHRF)
Category
Healthcare
EPS for Cipher Pharmaceuticals Inc. (CPHRF)
EPS as of June 2026 TTM: $1.13
According to Cipher Pharmaceuticals Inc.'s latest financial reports, its current EPS (TTM) is $1.13. At the end of 2025 the company had an EPS of $1.09, an increase over its 2024 EPS of $0.47.
EPS history for Cipher Pharmaceuticals Inc. from 2004 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $1.13 | 3.67% |
| 2025 | $1.09 | 131.91% |
| 2024 | $0.47 | -42.68% |
| 2023 | $0.82 | -18.81% |
| 2022 | $1.01 | 248.28% |
| 2021 | $0.29 | 61.11% |
| 2020 | $0.18 | 50.00% |
| 2019 | $0.12 | 491.13% |
| 2018 | $0.02 | -87.31% |
| 2017 | $0.16 | -110.74% |
| 2016 | $-1.49 | -2,228.57% |
| 2015 | $0.07 | -136.84% |
| 2014 | $-0.19 | -119.79% |
| 2013 | $0.96 | 860.00% |
| 2012 | $0.10 | -206.84% |
| 2011 | $-0.09 | -4,169.57% |
| 2010 | 0.00 | -102.09% |
| 2009 | $-0.11 | 0.00% |
| 2008 | $-0.11 | -59.26% |
| 2007 | $-0.27 | -38.64% |
| 2006 | $-0.44 | 29.41% |
| 2005 | $-0.34 | -27.66% |
| 2004 | $-0.47 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | 475.35% |
DE
|
|
| $6.08 | 437.84% |
DE
|
|
| $1.55 | 37.22% |
JP
|
|
| $3.66 | 223.89% |
CH
|
|
| $0.45 | -60.18% |
IL
|
Questions about Cipher Pharmaceuticals Inc.'s earnings per share (EPS)
What is Cipher Pharmaceuticals Inc.'s earnings per share (EPS)?
Cipher Pharmaceuticals Inc.'s earnings per share (EPS) over the last twelve months is $1.13, as of Jun 2026.
What was Cipher Pharmaceuticals Inc.'s earnings per share (EPS) in 2025?
In 2025, Cipher Pharmaceuticals Inc.'s earnings per share (EPS) was $1.09, 131.91% more than in 2024 ($0.47).
How has Cipher Pharmaceuticals Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Cipher Pharmaceuticals Inc.'s earnings per share (EPS) went from $0.18 to $1.09, an average growth of 43.36% a year.
How does Cipher Pharmaceuticals Inc.'s earnings per share (EPS) compare with similar companies?
Cipher Pharmaceuticals Inc.'s earnings per share (EPS) ($1.13) is higher than that of 1 of the 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.